About the Authors

Sara Westrøm

Affiliations Oncoinvent AS, Oslo, Norway, Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Tina B. Bønsdorff

Affiliation Oncoinvent AS, Oslo, Norway

Nasir Abbas

Affiliation Oncoinvent AS, Oslo, Norway

Øyvind S. Bruland

Affiliations Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

Thora J. Jonasdottir

Affiliation Oncoinvent AS, Oslo, Norway

Gunhild M. Mælandsmo

Affiliation Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway

Roy H. Larsen

royhlars1@yahoo.no

Affiliation Sciencons AS, Oslo, Norway

Competing Interests

The OI-3 monoclonal antibody is a patented product from Oncoinvent AS. Sara Westrøm and Tina B. Bønsdorff are employed by Oncoinvent AS, and Nasir Abbas and Thora J. Jonasdottir were employed by Oncoinvent AS at the time when their main contribution to the research article occurred. Oncoinvent AS provided support in the form of salaries for authors SW, TBB, NA and TJJ, but did not have any additional role in the study design, data collection and analysis, or preparation of the manuscript. Øyvind S. Bruland, Thora J. Jonasdottir and Roy H. Larsen are members of the Board of Oncoinvent AS, and the three of them together with Tina B. Bønsdorff are shareholders of Oncoinvent AS. Roy H. Larsen is also affiliated to Sciencons AS which is a shareholder of Oncoinvent AS. Sciencons AS did not provide support in the form of salaries for author Roy H. Larsen, and did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. A patent application related to the OI-3 antibody versions described in the submitted manuscript has previously been filed (Patent name: Monoclonal antibody and derivatives. Patent number: PCT/EP2014/070395). The authors confirm that these competing interests do not alter their adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceptualization: SW TBB ØSB TJJ RHL. Formal analysis: SW TBB. Funding acquisition: TBB ØSB TJJ GMM RHL. Investigation: SW TBB NA RHL. Methodology: TBB ØSB GMM RHL. Project administration: TJJ GMM. Resources: ØSB GMM RHL. Supervision: TBB ØSB RHL. Validation: SW TBB NA. Visualization: SW TBB. Writing – original draft: SW TBB NA ØSB TJJ GMM RHL. Writing – review & editing: SW TBB NA ØSB TJJ GMM RHL.